Avandra Imaging

Avandra Imaging is a clinical-stage biotechnology company specializing in the development of targeted radiopharmaceuticals for cancer theranostics. Founded by Dr. David Goldenberg, the pioneer behind Immunomedics, the company leverages a proprietary pre-targeting platform designed to optimize the therapeutic index of radioimmunotherapy. This approach utilizes bispecific antibodies that first localize to tumor-associated antigens, followed by the administration of a small-molecule radioactive payload that binds specifically to the antibody at the tumor site. By decoupling the targeting agent from the radioactive isotope, Avandra aims to maximize radiation delivery to tumors while minimizing systemic exposure and off-target toxicity. The company's lead programs focus on high-impact targets such as CEA and TROP2 for the treatment of various solid malignancies.